166 related articles for article (PubMed ID: 20594598)
1. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Martínez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Martinez-Zamora MA; Tassies D; Carmona F; Espinosa G; Cervera R; Reverter JC; Balasch J
Am J Reprod Immunol; 2009 Dec; 62(6):381-9. PubMed ID: 19895374
[TBL] [Abstract][Full Text] [Related]
3. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Martínez-Zamora MA; Creus M; Tassies D; Bové A; Reverter JC; Carmona F; Balasch J
Fertil Steril; 2010 Nov; 94(6):2437-40. PubMed ID: 20378110
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
Alacacioğlu I; Ozcan MA; Alacacioğlu A; Polat M; Yüksel F; Demirkan F; Pişkin O; Ozgenç Y; Ozsan HG; Undar B
Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211
[TBL] [Abstract][Full Text] [Related]
5. Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
Acosta-Tejeda M; Baptista-González H; Rosenfeld-Mann F; Trueba-Gómez R; García-Latorre E
Thromb Res; 2011 Oct; 128(4):e39-42. PubMed ID: 21708401
[TBL] [Abstract][Full Text] [Related]
6. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
8. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
9. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications.
Carmona F; Lázaro I; Reverter JC; Tàssies D; Font J; Cervera R; Balasch J
Am J Obstet Gynecol; 2006 Feb; 194(2):457-65. PubMed ID: 16458646
[TBL] [Abstract][Full Text] [Related]
10. [Effect of antiphospholipid antibodies on the formation and lysis of fibrin network in patients with recurrent miscarriage].
Marchi R; Maya I; Garmendia J
Invest Clin; 2011 Mar; 52(1):35-47. PubMed ID: 21614812
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
13. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
Antovic JP; Rafik Hamad R; Antovic A; Blombäck M; Bremme K
Thromb Haemost; 2002 Oct; 88(4):644-7. PubMed ID: 12362237
[TBL] [Abstract][Full Text] [Related]
14. Reduced plasma fibrin clot permeability and susceptibility to fibrinolysis are associated with increased intima-media thickness in patients with primary antiphospholipid syndrome.
Asztabski M; Wypasek E; Ząbczyk M; Undas A
Thromb Res; 2014 Nov; 134(5):945-51. PubMed ID: 25194881
[TBL] [Abstract][Full Text] [Related]
15. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome.
Tàssies D; Espinosa G; Muñoz-Rodríguez FJ; Freire C; Cervera R; Monteagudo J; Maragall S; Escolar G; Ingelmo M; Ordinas A; Font J; Reverter JC
Arthritis Rheum; 2000 Oct; 43(10):2349-58. PubMed ID: 11037896
[TBL] [Abstract][Full Text] [Related]
16. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome.
Forastiero R; Martinuzzo M; Adamczuk Y; Varela ML; Pombo G; Carreras LO
Haematologica; 2001 Jul; 86(7):735-41. PubMed ID: 11454529
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome.
Atsumi T; Khamashta MA; Andujar C; Leandro MJ; Amengual O; Ames PR; Hughes GR
J Rheumatol; 1998 Jan; 25(1):69-73. PubMed ID: 9458205
[TBL] [Abstract][Full Text] [Related]
19. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
Ieko M; Yoshida M; Naito S; Nakabayashi T; Kanazawa K; Mizukami K; Mukai M; Atsumi T; Koike T
Int J Hematol; 2010 Jun; 91(5):776-83. PubMed ID: 20490730
[TBL] [Abstract][Full Text] [Related]
20. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
